Other common effects include constipation, abdominal pain, and dyspepsia
Both sourcing facts are brand-stated and publicly disclosed
()
In response, the body focuses on essential bodily functions over menstruation and producing hormones like oestrogen
Lower doses may be reasonable for some patients, but microdosing is still off-label, and the strongest evidence still comes from standard therapeutic dosing in populations with clinical obesity or metabolic disease, and many of the broader claims around low-dose use exceed what the evidence supports
They function by mimicking natural hormones that control appetite, metabolism, and glucose levels in the body: Tirzepatide acts as both a GLP-1 and GIP receptor agonist, effectively reducing hunger while enhancing the bodys ability to burn fat